MedTrace Logo

Efficacy of Probiotics for Parkinson Disease (PD)

NCT06118294 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-04-23

No results posted yet for this study

Summary

In previous clinical studies, PS128 has been reported to ameliorate motor deficits in Parkinson's disease (PD). PS23 has been reported to delay some age-related disorders.

On the basis of previous animal and clinical studies which hope that this study can support the theory of the gut-brain axis, and have the opportunity to realize the relationship between peripheral inflammation and neurodegeneration.

Conditions

Interventions

DIETARY_SUPPLEMENT

probiotics

\>30 billion CFU/capsule

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Bened Biomedical Co., Ltd.

    collaborator INDUSTRY

  • Changhua Christian Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-08
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118294 on ClinicalTrials.gov